Optimization of methods for intrasplenic administration of human amniotic epithelial cells in order to perform safe and effective cell-based therapy for liver diseases
-
Published:2024-05-21
Issue:6
Volume:20
Page:1599-1617
-
ISSN:2629-3269
-
Container-title:Stem Cell Reviews and Reports
-
language:en
-
Short-container-title:Stem Cell Rev and Rep
Author:
Czekaj PiotrORCID, Król MateuszORCID, Kolanko EmanuelORCID, Wieczorek PatrycjaORCID, Bogunia EdytaORCID, Hermyt MateuszORCID, Grajoszek AnielaORCID, Prusek AgnieszkaORCID
Abstract
AbstractIn animal experimental models the administration of stem cells into the spleen should ensure high effectiveness of their implantation in the liver due to a direct vascular connection between the two organs. The aim of this study was to update the methods of experimental intrasplenic cell transplantation using human amniotic epithelial cells (hAECs) which are promising cells in the treatment of liver diseases. BALB/c mice were administered intrasplenically with 0.5, 1, and 2 million hAECs by direct bolus injection (400 µl/min) and via a subcutaneous splenic port by fast (20 μl/min) and slow (10 μl/min) infusion. The port was prepared by translocating the spleen to the skin pocket. The spleen, liver, and lungs were collected at 3 h, 6 h, and 24 h after the administration of cells. The distribution of hAECs, histopathological changes in the organs, complete blood count, and biochemical markers of liver damage were assessed. It has been shown that the method of intrasplenic cell administration affects the degree of liver damage. The largest number of mice showing significant liver damage was observed after direct administration and the lowest after slow administration through a port. Liver damage increased with the number of administered cells, which, paradoxically, resulted in increased liver colonization efficiency. It was concluded that the administration of 1 × 106 hAECs by slow infusion via a subcutaneous splenic port reduces the incidence of complications at the expense of a slight decrease in the effectiveness of implantation of the transplanted cells in the liver.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Strom, S. C., Skvorak, K., Gramignoli, R., Marongiu, F., & Miki, T. (2013). Translation of amnion stem cells to the clinic. Stem Cells and Development,22(1), 96–102. https://doi.org/10.1089/scd.2013.0391 2. Puppi, J., Strom, S. C., Hughes, R. D., Bansal, S., Castell, J. V., Dagher, I., Ellis, E. C., Nowak, G., Ericzon, B. G., Fox, I. J., Gómez-Lechón, M. J., Guha, C., Gupta, S., Mitry, R. R., Ohashi, K., Ott, M., Reid, L. M., Roy-Chowdhury, J., Sokal, E., … Dhawan, A. (2012). Improving the techniques for human hepatocyte transplantation: Report from a consensus meeting in London. Cell Transplantation,21(1), 1–10. https://doi.org/10.3727/096368911X566208 3. Gramignoli, R. (2016). Therapeutic use of human amnion-derived products: Cell-based therapy for liver disease. Current Pathobiology Reports,4, 157–167. https://doi.org/10.1007/s40139-016-0112-84 4. Banas, R. A., Trumpower, C., Bentlejewski, C., Marshall, V., Sing, G., & Zeevi, A. (2008). Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Human Immunology,69(6), 321–328. https://doi.org/10.1016/j.humimm.2008.04.007 5. Kolanko, E., Grajoszek, A., & Czekaj, P. (2021). Immunosuppressive potential of activated human amniotic cells in an experimental murine model of skin Allo- and Xenotransplantation. Frontiers in Medicine (Lausanne),8, 715590. https://doi.org/10.3389/fmed.2021.715590
|
|